# Hemogenyx Pharmaceuticals

Source: https://onco.cc/companies/hemogenyx-pharmaceuticals/  
OnCo record `hemogenyx-pharmaceuticals` (Company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Hemogenyx Pharmaceuticals is developing a CAR-T cell therapy, a patient's own immune cells engineered to attack cancer, aimed at the FLT3 protein on acute myeloid leukaemia cells. It is in a first trial at MD Anderson for leukaemia that has come back or stopped responding.

## Summary

Hemogenyx Pharmaceuticals plc is listed on the London Stock Exchange (HEMO) and headquartered at 6 Heddon Street, London, with its US operating subsidiaries, Hemogenyx Pharmaceuticals LLC and Immugenyx LLC, at a research facility on Amsterdam Avenue, New York. The company was incorporated in England and Wales on 13 February 2013 and admitted to the LSE on 5 October 2017, according to the company. HG-CT-1 (HEMO-CAR-T) is an autologous third-generation CAR-T using a proprietary humanised anti-FLT3 scFv that the company says does not compete with FLT3 ligand; a phase 1 study in relapsed or refractory AML at MD Anderson Cancer Center is registered (NCT06786533), and the company's pipeline page reported two patients dosed and a third recruited. A preclinical FLT3 x CD3 bispecific antibody (CDX) is also in development, with stated potential for bone marrow transplant conditioning. Its first registered cancer trial, NCT06786533, was posted on ClinicalTrials.gov in January 2025.

## Fields

- Kind: Company
- Last checked: 2026-10-29
- Also known as: Hemogenyx Pharmaceuticals plc
- HQ: London
- Type: cell-therapy
- Website: https://hemogenyx.com/
- Ticker: HEMO.L

## Notes

- Read on 29 October 2026: hemogenyx.com about, pipeline, investors, announcements and contact pages. The pipeline page's patient count may be out of date; the 2026 announcements (including an April 2026 institutional fundraise) were seen as titles only, so no funding rows are listed.
- The pipeline page states blood cancer incidence figures from 2014 and other claims that were not checked; they are not repeated.
- Trial facts from the ClinicalTrials.gov record NCT06786533, read on 29 October 2026.

## Sources

- Official website: https://hemogenyx.com/
- Pipeline: https://hemogenyx.com/pipeline/
- ClinicalTrials.gov: phase 1 trial of anti-FLT3 CAR-T cells in relapsed or refractory AML (NCT06786533): https://clinicaltrials.gov/study/NCT06786533

## Connected records

- cancers: [Acute myeloid leukaemia](https://onco.cc/cancers/aml/)
- fronts: [Cell Therapy](https://onco.cc/fronts/cell-therapy/), [Immunotherapy](https://onco.cc/fronts/immunotherapy/)
- technologies: [Bispecific antibodies](https://onco.cc/technologies/bispecific-antibody/), [CAR-T cell therapy](https://onco.cc/technologies/car-t/)
- targets: [CD3](https://onco.cc/targets/cd3/), [FLT3](https://onco.cc/targets/flt3/)

---
JSON: https://onco.cc/api/v1/entities/hemogenyx-pharmaceuticals.json